News | May 03, 2025
SMS Pharmaceuticals’ Vizag plant receives WHO Geneva prequalification
This significant milestone enhances our global regulatory standing
This significant milestone enhances our global regulatory standing
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
The inspection conducted by EDQM at its Visakhapatnam facility
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
With this, the company can start selling Ibuprofen in the European markets.
The new logo is a refreshing change from the version that has served Hetero well for three decades. And yet its reflection can be seen in the new version
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Subscribe To Our Newsletter & Stay Updated
